NEW YORK, NY / ACCESSWIRE / November 9, 2017 / U.S. markets pushed higher Wednesday on the strength of corporate earnings on the anniversary of President Trump's election. The Dow Jones Industrial Average edged out a 0.03 percent gain to close at 23,563.36, up approximately 31.72 percent in the past year, while the S&P 500 Index rose 0.14 percent to close at 2,594.38, up approximately 24.42 percent in the past year. The Nasdaq Composite Index increased 0.32 percent to close at 6,789.12, up approximately 34.53 percent in the past year. Earnings for the S&P 500 are estimated to have grown by approximately 8 percent in the third quarter, up from expectations of a 5.9 percent growth at the beginning of October, according to Thomson Reuters I/B/E/S.
RDI Initiates Coverage on:
ACADIA Pharmaceuticals Inc.
Spark Therapeutics, Inc.
ACADIA Pharmaceuticals stock moved 9.40% lower Wednesday, to close the day at $29.41. The stock recorded a trading volume of 6,030,261 shares, which was above its three months average volume of 1,497,996 shares. In the last year, ACADIA Pharmaceuticals shares have traded in a range of 24.31 - 41.20. The share price has gained 20.98% from its 52-week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $36.40 is greater than its 200-day moving average of $31.94. Shares of ACADIA Pharmaceuticals have fallen roughly 23.69 percent in the past month and are up 1.98 percent year-to-date.
Access RDI's ACADIA Pharmaceuticals Inc. Research Report at:
On Wednesday, shares in Spark Therapeutics, Inc. recorded a trading volume of 940,303 shares, which was above the three months average volume of 449,316 shares. The stock ended the day 7.34% lower at 73.93. The share price has gained 57.20% from its 52-week low with a 52-week trading range of 47.03 - 91.75.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $84.80 is greater than its 200-day moving average of $70.84. Shares of Spark Therapeutics have fallen roughly 15.45 percent in the past month and are up 48.16 percent year-to-date.
Access RDI's Spark Therapeutics, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.